Coherus BioSciences (CHRS) Tops Q4 EPS by 2c
Tweet
Share
E-mailGet Alerts CHRS Hot Sheet
Price: $1.52 --0%
EPS Growth %: +23.5%
Financial Fact:
Diluted net income/(loss) per share: 0.15
Today's EPS Names:
YRD, NNOX, BB, More
EPS Growth %: +23.5%
Financial Fact:
Diluted net income/(loss) per share: 0.15
Today's EPS Names:
YRD, NNOX, BB, More
Join SI Premium – FREE
Coherus BioSciences (NASDAQ: CHRS) reported Q4 EPS of ($0.28), $0.02 better than the analyst estimate of ($0.30). Revenue for the quarter came in at $54.14 million versus the consensus estimate of $44.15 million.
For earnings history and earnings-related data on Coherus BioSciences (CHRS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs (GS) Reiterated at Market Perform by Citizens on Constructive Backdrop
- RBC Capital Upgrades ICON plc (ICLR) to Outperform
- DraftKings Inc. (DKNG) PT Raised to $36 at Citizens on Prediction Market Opportunity
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
